SCHEMBL5459337

SCHEMBL5459337

CCOC(=O)CCCC1=NN(c2ccc(Cl)cc2)C(=O)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.62
RAB9A P51151 3/20 0.62
NPC1 O15118 2/20 0.62
KDM4E B2RXH2 2/20 0.62
KMT2A Q03164 5/20 0.51
ALDH1A1 P00352 5/20 0.51
MEN1 O00255 4/20 0.51
LMNA P02545 4/20 0.51
TDP1 Q9NUW8 3/20 0.51
HTT P42858 2/20 0.51
GAA P10253 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
SHMT2 P34897 1/20 0.44
P2RX7 Q99572 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928911 0.88 GAA (0.60) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL5462729 0.81 GAA (0.63) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL5975777 0.80 KMT2A (0.60) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL8427533 0.77 MAPT (0.65) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL8425819 0.76 MEN1 (0.60) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL4664663 0.74 GAA (0.76) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL6953402 0.74 GAA (0.60) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL8428145 0.73 GAA (0.46) MAPTRAB9ANPC1KDM4EKMT2A
SCHEMBL4467166 0.72 CYP4F2 (0.58) MAPTALDH1A1TDP1GAACYP1A2
SCHEMBL8428093 0.72 GAA (0.47) MAPTRAB9ANPC1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MAPT 4163/4885RAB9A 3765/4885NPC1 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.